18 February 2022
Shield Provides Full Year Trading Update and Reports Progress on the Commercialization of Accrufer®/Feraccru®
Shield Therapeutics is pleased to provide an update on trading for the year ended 31 December 2021, as well as an update on the Company’s progress on the commercialization of its lead product Accrufer®/Feraccru® (ferric maltol), an effective, well tolerated, low-dose novel formulation of oral iron replacement therapy with an adverse event profile and discontinuation rate well below the published 40-60% rate for conventional oral iron therapy.
For more details click here.